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remains nonpathogenic for humans,
although a case of human infection
without clinical signs has been
described in the Czech Republic (9).
Blood serum samples from 710
randomly selected persons >20 years
of age from the Czech Republic were
screened for antibodies against
Puumala and Hantaan antigens with
commercial enzyme-linked immuno-
sorbent assay (ELISA) sets manufac-
tured by PROGEN (Biotechnik,
Heidelberg, Germany). The Hantaan
antigen was used because of its anti-
genic relatedness with Dobrava virus,
which is not included in available
commercial ELISA sets.
Five participants showed immuno-
globulin (Ig) G reactivity to Hantaan
virus (cross-reactive with Dobrava
antigen), and two participants tested
positive for both IgG and IgM anti-
bodies. Two other persons showed
IgM reactivity alone. These findings
indicate that as many as seven (1.0%)
study participants showed reactivity
to Hantaan antigen. Eight persons
showed IgG reactivity to Puumala
antigen, none of them IgM positive.
Altogether, 10 (1.4%) study partici-
pants were reactive to Puumala anti-
gen. Three persons showed reactivity
to both antigens tested.
Atotal of 1,494 small mammals of
different Czech regions were screened
with ELISA for hantavirus antigen in
the lungs. The antigen was detected in
the lungs of 101 animals; the highest
positivity rate was in Common Voles
(Microtus arvalis). The difference in
positivity between male and female
voles was not statistically significant.
The positivity rate was markedly
associated with rodent size. With the
use of molecular genetic methods
(polymerase chain reaction), genotype
Tula was identified as the causative
agent of infection in rodents.
Genotype Puumala was identified in
bank voles (Clethrionomys glareolus)
in Moravia. Nucleotide sequences
of Dobrava genotype were identified
in southern Bohemian rodents
(K. Krivanec, pers. comm.).
In the Czech Republic, Tula virus
is the most frequent hantavirus circu-
lating in Common Voles. This agent is
not pathogenic for humans. The han-
tavirus seroprevalence rate in the
adult population of the Czech
Republic is close to 1%. Dobrava and
Puumala viruses are causative agents
of these infections in humans. 
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To the Editor: Medical events
during airline flights have drawn some
attention in recently published articles
and letters (1–4). We would like to
share our experience of meningococ-
cemia/ and meningococcal meningitis
during a transatlantic flight.
In June 2000, a 20-year-old stu-
dent with a mild viral illness (diag-
nosed before the flight) boarded a
flight from Tel-Aviv, Israel, to
Newark, New-Jersey, USA (approxi-
mate flight time, 11–12 hours), with a
tour group of college-age students and
their chaperones. We, a neonatologist
and a neonatal intensive care nurse,
were on the same flight to later trans-
port a prematurely born infant from
the United States back to Israel.
About 90 minutes before landing
in New Jersey, the chief flight atten-
dant asked me (B.B-O.) to check the
passenger, who said he did not feel
well. His medical history indicated no
past illness, which was corroborated
by the director of the tour group. The
patient reported general malaise and
numbness in his feet. In the 2 weeks
before the flight, he had traveled in
Israel, visiting cities, caves, and
mountains. He and his group had slept
in different hostels in those areas. 
On examination, he was fully con-
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pulse rate were normal. He had a
blue-purple skin rash, particularly on
the upper extremities. The rash wors-
ened in the course of 20 minutes and
resembled the “blueberry muffin–
like” rash described in other patholog-
ic conditions. Considering a diagnosis
of either tick-borne or meningococcal
disease, I decided to give the patient
the first dose of antibiotics after
obtaining a verbal consent from him
and from the head of the group. I also
asked the crew to have an ambulance
and a physician waiting for us at the
destination airport. 
When we checked the emergency
medical kit, we found that it did not
contain any antibiotics. For our trans-
port mission, we had two ampules of
cefotaxime, 2 g each, one of which we
gave the patient. After we landed, an
ambulance crew (which did not
include a physician) took the patient
to the nearest hospital. The patient
died 2 hours later in the hospital emer-
gency department. His laboratory
tests showed meningococcal meningi-
tis and meningococcemia. The
Centers for Disease Control (CDC),
the airline company, and Israel’s
Ministry of Health notified all close
contacts of the patient in Israel and
during the transatlantic flight, includ-
ing everyone in the tour group, and
recommended that they be given
chemoprophylaxis. 
CDC has received 21 reports about
air travel–associated meningococcal
disease in 2 years; in 5 reports, the
symptoms began before the plane
arrived at its destination (5).
However, advance notice of the symp-
toms was given only in our case.
Although one case is not enough to
substantiate recommendations, we
believe that the appropriate authori-
ties should require airline companies
to add a broad-spectrum antibiotic
preparation to the emergency kit. This
drug should be used only when air-
craft diversion is not possible and
when the diagnosis is clinically iden-
tified or highly suspected.  
We still wonder whether an earlier
intervention and treatment with a
more appropriate on-board antibiotic
treatment would have saved this
young man.
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